Drugs / Neurontin
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | NEURONTIN | — | 1998-09-29 – 2002-08-15 | fda.gov ↗ |
| Approved | US (FDA) | NEURONTIN | — | 1993-12-30 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04240626 | Jan 2021 → Jun 2026 overdue | morbid obesity | University of California, Davis | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01489631 Comparator | Mar 2013 → Apr 2014 | — | St. Antonius Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | neurontin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01489631 ↗ |
| Route | Intravenous | “Gabapentin via IV” NCT04240626 ↗ |